Sugi Predict

Sugi Predict / Compounds / SCHEMBL375852

SCHEMBL375852

SCHEMBL375852

CC(C)(C)OC(=O)N1CCN(C(=O)OCc2ccccc2)C(C(=O)O)C1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 1/20 0.55
▸ PDK2 Q15119 1/20 0.55
▸ PDK3 Q15120 1/20 0.55
▸ PDK4 Q16654 1/20 0.55
▸ PARP1 P09874 1/20 0.53
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ JAK2 O60674 1/20 0.47
▸ JAK1 P23458 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PREP P48147 1/20 0.46
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933923 1.00 PDK1 (0.55) PDK1PDK2PDK3PDK4PARP1
SCHEMBL2442588 1.00 PDK1 (0.55) PDK1PDK2PDK3PDK4PARP1
SCHEMBL1375861 0.95 PARP1 (0.58) PDK1PDK2PDK3PDK4PARP1
SCHEMBL957813 0.95 PARP1 (0.58) PDK1PDK2PDK3PDK4PARP1
SCHEMBL3766378 0.95 PARP1 (0.58) PDK1PDK2PDK3PDK4PARP1
SCHEMBL7493594 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL30289331 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL7492256 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL3779343 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL30729617 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026101698-A1 HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF PROTAGONIST THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-12582645-B2 Chemokine CXCR4 receptor modulators and uses related thereto EMORY UNIVERSITY (US) 2026-03-24 — — US disclosed
US-20250368625-A1 PIPERAZINES Grünenthal GmbH (DE) 2025-12-04 — — US disclosed
US-12319679-B2 Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-06-03 — — US disclosed
US-20240409556-A1 BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. 2024-12-12 — — US disclosed
US-12162893-B2 Tricyclic pyridones and pyrimidones ERASCA, INC. (US) 2024-12-10 — — US disclosed
US-20240316034-A1 Chemokine CXCR4 Receptor Modulators and Uses Related Thereto UNIV EMORY (US) 2024-09-26 — — US disclosed
EP-4327814-A2 MORPHOLINYL, PIPERAZINYL, OXAZEPANYL AND DIAZEPANYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS Biogen MA Inc. (US) 2024-02-28 — — EP disclosed
EP-3490993-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2023-12-06 — — EP disclosed
WO-2023178378-A1 MIP INHIBITORS DMTC Limited (AU) 2023-09-28 — — WO disclosed
US-5736539-A ANITCARCINOGENIC AGENTS MERCK & CO., INC. (US) 1998-04-07 — — US disclosed
US-5652369-A PROTEASE INHIBITOR HOFFMANN-LA ROCHE INC. (US) 1997-07-29 — — US disclosed
US-5620987-A Amino acid derivatives HOFFMANN-LA ROCHE INC. (US) 1997-04-15 — — US disclosed
US-5554756-A PROTEASE INHIBITOR HOFFMANN-LA ROCHE INC. (US) 1996-09-10 — — US disclosed
EP-0703905-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO. INC. (US) 1996-04-03 — — EP disclosed
US-5446161-A Protease inhibitor, viricides HOFFMANN-LA ROCHE INC. (US) 1995-08-29 — — US disclosed
WO-1995000497-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1995-01-05 — — WO disclosed
EP-0346847-B1 Amino acid derivatives HOFFMANN LA ROCHE (CH) 1994-05-11 — — EP disclosed
US-5157041-A Viricides HOFFMANN-LA ROCHE INC. (US) 1992-10-20 — — US disclosed
EP-0346847-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1989-12-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316034-A1 Chemokine CXCR4 Receptor Modulators and Uses Related Thereto CXCR4, CXCL12, CXCR1 PDK1 341/4885PDK2 1333/4885PDK3 1491/4885
US-20240409556-A1 BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD YAP1, TEAD2, TEAD3 PDK1 91/4885PDK2 309/4885PDK3 277/4885
US-12319679-B2 Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors MAN2A1, MAN2B2, MGAT3 PDK1 1670/4885PDK2 1099/4885PDK3 2132/4885
US-12162893-B2 Tricyclic pyridones and pyrimidones DHFR, TYMS, TYMP PDK1 1153/4885PDK2 333/4885PDK3 874/4885
US-12582645-B2 Chemokine CXCR4 receptor modulators and uses related thereto CXCR4, CXCR2, CXCR1 PDK1 676/4885PDK2 2150/4885PDK3 2321/4885
US-20250368625-A1 PIPERAZINES SSTR4, SSTR5, SSTR2 PDK1 2761/4885PDK2 1452/4885PDK3 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.